InhaTarget Therapeutics
InhaTarget Therapeutics develops innovative inhalation formulations for severe respiratory diseases, with initial focus on lung cancer treatment.
InhaTarget Therapeutics is a spin-off from the University of Brussels (ULB) dedicated to early development and clinical validation of innovative pulmonary disease treatments via inhalation. The company brings together expertise in drug formulation, inhalation delivery, immunology, preclinical development, and clinical operations, aiming to improve existing molecules through novel treatment modalities.
Key People
- Frédéric De Coninck - Co-founder CEO
- Rémi Rosière - Co-founder CSO
- Karim Amighi - Co-founder and Scientific Advisor
Nathalie Wauthoz - Co-founder and Scientific Advisor